Thursday, June 25, 2020 7:38:09 PM
$ZYNE | #Zynerba Trade Setup
Very high short interest at 30%
Stock is currently well below the average analyst price target of $18 and a BUY rating.
Company profile
Zynerba Pharmaceuticals , Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. It offers Zygel product which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
Official InvestorsHub (IHUB) Profile for #TFMG | #theFinancialMarketingGroup:
#BullishCharts - https://investorshub.advfn.com/BullishChartscom-38003/
#TopMarketGainers - https://investorshub.advfn.com/Chart-Analysis-TopMarketGainerscom-36847/
Recent ZYNE News
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
